Pharmaceutical - GlaxoSmithKline, Gastro-intestinals

Filter

Popular Filters

ChemoCentryx plunges as partnered drug candidate fails to meet endpoints

26-08-2013

US drug developer ChemoCentryx (Nasdaq: CCXI) saw its shares plummet 31.6% to $7.99 last Friday (August…

ChemoCentryxGastro-intestinalsGlaxoSmithKlinePharmaceuticalResearch

Research news: dolutegravir; TD-1211; and synaptic modulators

11-07-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) and Japanese drugmaker Shionogi (TYO: 4507) have reported…

Anti-viralsdolutegravirGalenea CorpGastro-intestinalsGlaxoSmithKlineLicensingNeurologicalPharmaceuticalRegulationResearchShionogiTD-1211TheravanceZonegran

Back to top